Welcome to our dedicated page for Lifeward Ltd. SEC filings (Ticker: LFWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lifeward Ltd. filings document regulatory disclosures for a Nasdaq-listed medical technology company whose ordinary shares trade under LFWD. The filing record includes Form 8-K material-event reports, annual-report references, shareholder vote results, and disclosures tied to its rehabilitation and recovery technology business.
Recent filings cover a completed acquisition, related ordinary-share and warrant consideration, a reverse share split, amendments to articles of association, authorized share-capital changes, and Nasdaq listing-compliance matters. The filings also document board and audit committee governance, officer employment and compensation arrangements, operating and financial results, material agreements, risk factors, and clinical or regulatory disclosures.
Lifeward Ltd. reported second-quarter 2026 revenue of $6.6 million, up modestly from $5.7 million a year earlier, with six-month revenue essentially flat at $10.5 million versus $10.8 million in 2025. Gross profit for the first half was $4.1 million, down from $4.6 million.
The company posted a six‑month net loss of $22.3 million, nearly double the prior-year loss of $11.4 million, driven largely by $7.8 million in net financial expense from warrant and derivative liabilities and interest on new convertible notes. Operating cash outflow was $9.7 million. Management states that recurring losses, negative cash flows and limited liquidity raise substantial doubt about Lifeward’s ability to continue as a going concern without additional financing.
During the period, Lifeward closed the Oratech asset acquisition, allocating $4.9 million to in‑process R&D (expensed immediately) and $6.5 million to acquired cash, and completed the Skelable technology acquisition. It also issued $10 million of senior secured convertible notes with attached warrants and, in a July closing, added $5.6 million more in senior secured convertible notes, while reclassifying certain warrant and derivative liabilities to equity.
Lifeward Ltd. reported second quarter 2026 results showing higher revenue but a larger net loss, alongside significant leadership changes. Revenue increased 16% to $6.6 million from $5.7 million a year earlier, driven by ReWalk Personal exoskeleton sales of $2.5 million and AlterG products and services of $4.1 million. Gross margin was 41%, down from 44% due to higher tariffs, foreign exchange impacts and a 4% revenue-sharing expense tied to the Oramed transaction.
Total operating expenses declined 24% to $6.9 million, reflecting prior-year impairment charges, and operating loss improved 37% to $4.2 million. However, net loss widened to $11.5 million (or $4.12 per share) from $6.6 million, mainly from non-cash fair value charges on warrant and derivative liabilities. On a non-GAAP basis, net loss was $4.1 million. Cash and cash equivalents rose to $9.4 million as of June 30, 2026, versus $2.2 million at year-end 2025, with a pro forma balance of about $11 million including a July 2026 capital raise.
Governance changes include the resignations of directors Robert J. Marshall, Jr., Michael Swinford and William Mark Sigsbee, effective August 13, 2026, with no disagreements cited. Chief Financial Officer Almog Adar will step down effective September 30, 2026, under a separation agreement treated as a termination without cause while he supports the transition.
Lifeward Ltd., an Israeli medical device company focused on exoskeletons and rehabilitation technologies, is registering for resale up to 2,066,662 ordinary shares. These consist of 1,033,331 shares issuable upon conversion of senior secured convertible notes and 1,033,331 shares issuable upon exercise of accompanying warrants from a June 30, 2026 Note and Warrant Financing.
The Initial Notes total $5,580,000 in principal, bear 8% annual interest, mature three years from their original issue date and are convertible at $5.40 per share. The Initial Warrants are immediately exercisable at $5.40 per share for five years. Lifeward is not selling shares in this offering and will receive no proceeds from Selling Shareholder resales, though it may receive cash from any warrant exercises for general corporate purposes. As of July 31, 2026, 2,828,362 ordinary shares were outstanding, and the Nasdaq Capital Market closing price was $7.22 under the symbol “LFWD.” The filing notes a 4.99% Beneficial Ownership Limitation for conversions and exercises and references an audit opinion containing a going concern explanatory paragraph.
Lifeward Ltd., an Israel-incorporated health care biotechnology company limited by shares with principal offices in Hudson, Massachusetts, is conducting an exempt private offering under Regulation D Rule 506(b). The company reports that it has sold $11,160,000 USD of securities.
The offering covers multiple instruments, including equity, debt, options or warrants or other rights to acquire securities, and the underlying securities issuable upon exercise of those rights. This is a new notice, with the first sale occurring on 2026-07-06. The company discloses $0 in finders' fees associated with the offering.
Lifeward Ltd. entered into a new financing arrangement built around senior secured convertible notes and warrants. The company closed an initial issuance of $5,580,000 in notes on July 6, 2026, with a second $5,580,000 tranche available upon meeting performance or share-price conditions.
Each note has a three-year term, carries 8.0% annual interest (rising to 15.0% on default) and is convertible into ordinary shares at an initial price of $5.40 per share. Investors also receive warrants exercisable for up to 100% of the shares underlying each note, also at $5.40 per share, immediately exercisable and expiring after five years. Both notes and warrants include a 4.99% beneficial ownership cap and a 19.99% exchange cap on total share issuance unless shareholders approve more. The securities were sold in a private offering to accredited investors under Rule 506(b) of Regulation D.
Lifeward Ltd. reported a sharply wider quarterly loss while closing a major strategic transaction and related financing. For the three months ended March 31, 2026, revenue was $3.9 million, down from $5.0 million, mainly from lower AlterG Anti-Gravity system shipments, and gross margin fell to 34.2% from 42.2%. Net loss increased to $10.8 million, driven largely by a one-time $4.9 million acquired in‑process R&D charge from the Oratech asset acquisition and higher interest expense on new convertible notes. On March 25, 2026, Lifeward acquired Oratech for total consideration of about $12.4 million and issued $10.0 million of secured convertible notes and related warrants to Oramed and Creative Value Capital at a $5.40 per share conversion price. Cash and cash equivalents rose to $11.4 million after the Oratech cash acquired and note financing, but the company disclosed an accumulated deficit of $295.5 million and concluded that “substantial doubt” exists about its ability to continue as a going concern without additional capital.
Rose Keith Dale reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. reported that Chief Medical Officer Rose Keith Dale received an equity award of 15,000 ordinary shares in the form of restricted stock units. The RSUs were granted on May 1, 2026 under the company’s 2025 Incentive Compensation Plan.
The RSUs vest in four equal annual installments starting on the grant date, meaning a portion becomes deliverable each year over four years as long as vesting conditions are met. Following this award, Dale is shown as beneficially owning 17,083 ordinary shares directly.
Lifeward Ltd. Chief Medical Officer Rose Keith Dale filed an initial Form 3 reporting her equity position in the company. The filing lists direct ownership of 2,083 ordinary shares of no par value as of May 1, 2026, and does not report any share purchases or sales.
Lifeward Ltd. appointed Keith D. Rose, M.D. as its Chief Medical Officer, effective May 1, 2026. He has served in several senior medical affairs roles at the company since March 2023, most recently as Vice President, Medical Affairs, Medical Director – Neurosciences.
Before joining Lifeward, Dr. Rose held medical leadership positions at Biocodex, Novocure, Ipsen, Jazz Pharmaceuticals and Indivior. He earned his medical degree with distinction from The George Washington University and completed a five-year residency in Physical Medicine & Rehabilitation and Pediatric Medicine at Baylor College of Medicine.